Related Experiment Video
Updated: Jun 13, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
RAGE and the pathogenesis of chronic kidney disease
Vivette D'Agati1, Ann Marie Schmidt
1Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA.
Abstract:
The multiligand receptor of the immunoglobulin superfamily, receptor for advanced glycation endproducts (RAGE), is a signal transduction receptor that binds advanced glycation endproducts, certain members of the S100/calgranulin family of proteins, high mobility group box 1 (HMGB1), advanced oxidation protein products, and amyloid (beta-sheet fibrils). Initial studies investigating the role of RAGE in renal dysfunction focused on diabetes. However, RAGE also has roles in the pathogenesis of renal disorders that are not associated with diabetes, such as obesity-related glomerulopathy, doxorubicin-induced nephropathy, hypertensive nephropathy, lupus nephritis, renal amyloidosis, and ischemic renal injuries. Experiments that have employed transgenic mouse models, pharmacological blockade of RAGE, or genetic deletion or modification of RAGE indicate that modulation of RAGE expression or function affects the functional and pathological properties of these nephropathies. Accumulating evidence links RAGE to the pathogenesis of nephropathies, indicating that antagonism of RAGE might be a strategy for the treatment of chronic kidney disease.
Insights
The receptor for advanced glycation endproducts (RAGE) plays a key role in kidney disease beyond diabetes. Targeting RAGE may offer a new treatment strategy for chronic kidney disease.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- The receptor for advanced glycation endproducts (RAGE) is a multiligand signal transduction receptor.
- RAGE binds various ligands including advanced glycation endproducts, S100 proteins, HMGB1, advanced oxidation protein products, and amyloid fibrils.
- While initially studied in diabetic nephropathy, RAGE is implicated in other kidney diseases.
Purpose of the Study:
- To explore the role of RAGE in the pathogenesis of non-diabetic renal disorders.
- To investigate the potential of RAGE antagonism as a therapeutic strategy for chronic kidney disease.
Main Methods:
- Review of existing literature and experimental data.
- Analysis of studies using transgenic mouse models with altered RAGE expression or function.
- Examination of research involving pharmacological blockade or genetic deletion/modification of RAGE.
Main Results:
- RAGE is involved in the pathogenesis of obesity-related glomerulopathy, doxorubicin-induced nephropathy, hypertensive nephropathy, lupus nephritis, renal amyloidosis, and ischemic renal injuries.
- Modulation of RAGE expression or function impacts the functional and pathological characteristics of these nephropathies.
- Evidence suggests a significant link between RAGE and the development of various kidney diseases.
Conclusions:
- RAGE is a critical factor in the development of diverse nephropathies, not limited to diabetic kidney disease.
- Antagonism of RAGE presents a promising therapeutic avenue for managing chronic kidney disease.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Nephrons